Anatara Lifesciences Limited provided an update on progress of clinical trials in psychological functioning and irritable bowel syndrome, diarrhoea subtype (IBS-D). On 16 November at the AGM, Anatara anticipated commencing recruitment for the psychological functioning trial by the end of November and interim results for the IBS-D trial in April 2022. Anatara is adding an additional site in Adelaide for the IBS-D trial which will target recruitment of up to 50 participants and has engaged Evrima, a specialist in patient identification and recruitment. Evrima will support Anatara's IBS-D trial by both direct-to-patient and direct-to-clinician channels. Direct-to-patient will increase community awareness via social media, digital marketing campaigns and radio advertising. Direct-to-clinician will generate awareness within the GP community, as well as through the use of their proprietary software to identify potentially eligible patients via electronic health records in Australia. 3FDC is one of the components of Anatara's GaRP (Gastrointestinal reprogramming) complementary medicine. GaRP is a combination of two different minitablets, which is under investigation in another study focused on diarrhoea predominant Irritable bowel syndrome (IBS-D). The different minitablets in the formulation target different parts of the gastrointestinal tract. 3FDC is targeted to release at the junction between the small and large intestine (ileocecal junction) and exert its effects on the microbiome in the large intestine. Since restoration of a healthy microbiome is considered important for gut-brain axis balance, the 3FDC components have been selected to explore their effect on depression, anxiety and stress symptoms in otherwise healthy individuals.